Growth and endocrine effects of recombinant bovine growth hormone treatment in non-transgenic and growth hormone transgenic coho salmon

2012 ◽  
Vol 177 (1) ◽  
pp. 143-152 ◽  
Author(s):  
P.A. Raven ◽  
D. Sakhrani ◽  
B. Beckman ◽  
L. Neregård ◽  
L.F. Sundström ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Treatment ◽  
Coho Salmon ◽  
Hormone Treatment ◽  
Bovine Growth Hormone ◽  
Endocrine Effects

scholarly journals Late Endocrine Effects After HSCT in Children With Nonmalignant Diseases; A Single Center Cohort Analysis

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A668-A669
Author(s):  
Liselotte C de Kloet ◽  
Joëll E Bense ◽  
Eileen van der Stoep-Yap ◽  
Marloes Louwerens ◽  
Erik G J von Asmuth ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Late Effects ◽  
Growth Hormone Treatment ◽  
Bone Marrow Failure ◽  
Hormone Treatment ◽  
Endocrine Effects ◽  
Hematopoietic Stem ◽  
Gonadal Dysfunction ◽  
Endocrine Complications

Abstract Endocrine complications are amongst the most frequent late effects after pediatric hematopoietic stem cell transplantation (HSCT) for malignant diseases. Little is known about the prevalence and risk factors of endocrine complications in children transplanted for nonmalignant diseases. This retrospective study included 134 males and 63 females transplanted for a non-malignant disease between 1997 and 2018 with at least 2 years of follow up. Endocrine late effects and growth were evaluated. Gonadal dysfunction was defined as transient or permanent elevation of gonadotropins or hypogonadotropic hypogonadism. Median age at HSCT was 5.7 years (IQR 2.8-11.3) and median follow-up was 6.2 years (IQR 3.0-10.4). Underlying diseases were inborn errors of immunity (n=74), hemoglobinopathies (n=66) and bone marrow failure (n=57). The majority of patients had received busulfan-based conditioning (46%) or treosulfan-based conditioning (34%). Gonadal dysfunction occurred in 24/44 (post)pubertal female patients (55%) and was permanent in 19/44 (43%). 22/44 received hormonal substitution, which could be discontinued in 7. In females who received busulfan-based conditioning 16/17 (94%) developed gonadal dysfunction compared to 5/15 (33%) patients with treosulfan-based conditioning; the odds ratio for permanent gonadal dysfunction was 18.7 (3.61-135, p=0.001). Gonadal dysfunction occurred in 28/66 (post)pubertal male patients (42%) and was permanent in 23/66 (35%). 6/66 received hormonal substitution, which could be discontinued in 1. Gonadal dysfunction was more common in males (post)pubertal at HSCT, 14/21 (67%), compared to those prepubertal at HSCT, 14/45 (31%), p=0.014. 3/15 treated with a treosulfan-based regimen (20%) developed gonadal dysfunction, all transient, versus 19/39 with a busulfan-based regimen (49%), with 2 transient. 29/187 patients developed hypothyroidism (16%), 7 patients received thyroxine treatment (4%). All patients with persistent primary hypothyroidism (n=6) had positive TPO-antibodies. 17 patients received growth hormone treatment and were excluded from analysis. In patients without growth hormone treatment near adult height (NAH) was -1.2 SDS (median, IQR -2.0- -0.3) below mean parental height (MPH) in males and -0.4 SDS (median, IQR -1.6-0.3) in females. NAH below -2 SDS was seen in 13/43 males (30%) and 2/36 females (6%). The majority of these patients already had a height below -2 SDS before HSCT (73%). In conclusion, this study on late endocrine effects after HSCT in children with nonmalignant diseases indicates frequent gonadal dysfunction, present in 55% of females and 42% of males. In this cohort, risk of gonadal dysfunction in females was higher after busulfan-based conditioning than treosulfan-based conditioning. Careful long-term endocrine follow-up is indicated.

Evidence that bovine growth hormone treatment increases the rate of extrathyroidal 5′-monodeiodinase activity in cattle

1990 ◽  
Vol 7 (2) ◽  
pp. 125-134 ◽  
Author(s):  
T.S. Rumsey ◽  
S. Kahl ◽  
S.A. Norton ◽  
J. Eisemann ◽  
T.H. Elsasser ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Treatment ◽  
Hormone Treatment ◽  
Bovine Growth Hormone

THE PRODUCTION OF 'SULPHATION FACTOR' BY RAT LIVER

1972 ◽  
Vol 52 (1) ◽  
pp. 1-9 ◽  
Author(s):  
P. McCONAGHEY
Keyword(s):  
Growth Hormone ◽  
Rat Liver ◽  
Growth Hormone Treatment ◽  
Hormone Treatment ◽  
Humoral Factor ◽  
Bovine Growth Hormone ◽  
Freezing And Thawing ◽  
Cartilage Growth ◽  
Factor Production ◽  
Liver Slices

SUMMARY Rat liver when treated with bovine growth hormone produced a humoral factor ('sulphation factor') which stimulated cartilage growth directly; the results indicate that this humoral factor differs from growth hormone. Perfusion of rat liver and incubation of rat liver slices with bovine growth hormone stimulated the production of 'sulphation factor' as measured by the uptake of 35S into rat cartilage. The liver required a long exposure to the hormone before the 'sulphation factor' was produced and was still capable of 'sulphation factor' production after growth hormone treatment had ceased. The age and condition of the animal influenced the time necessary for growth hormone to act on the liver and the persistence of its effects. Disruption of liver slices by freezing and thawing, and by homogenization, destroyed their ability to produce 'sulphation factor' on addition of growth hormone.

Effect of glucocorticoid and growth hormone treatment on proinsulin levels in humans

Diabetes ◽  
1993 ◽  
Vol 42 (7) ◽  
pp. 1082-1085 ◽  
Author(s):  
S. E. Kahn ◽  
F. F. Horber ◽  
R. L. Prigeon ◽  
M. W. Haymond ◽  
D. Porte
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Treatment ◽  
Hormone Treatment
Sign in / Sign up

Export Citation Format

Share Document